# Vaxcyte, Inc. Common Stock (PCVX)

> Vaxcyte, Inc. Common Stock (PCVX) trades at $55.39 (-5.09%) as of 7:30:05 PM EST on Nov 20, 2026, -11.87% over the past month. Market cap is $8.77B, with 6.7 days to cover in short interest.

Canonical: https://massive.com/quote/pcvx
Data as of: 2026-11-21T00:30:05.739Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$55.39** -2.97 (-5.09%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$55.72** +0.33 (+0.60%)
As of 7:30:05 PM EST on Nov 20, 2026 · After hours

## Stock performance

How Vaxcyte, Inc. Common Stock (PCVX) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -5.09% |
| 1W | -12.59% |
| 1M | -11.87% |
| YTD | +20.05% |
| 1Y | +12.47% |
| 52-wk range | $42.40 – $90.75 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for PCVX: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $55.27 – $58.48 |
| Open | $57.77 |
| Prev close | $58.36 |
| Volume | 1.91M |
| Market cap | $8.77B |
| Shares out | 158.3M |

## Valuation and profitability ratios

Valuation and profitability ratios for Vaxcyte, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 3.52 |
| P/FCF | — |
| ROE | -46.1% |
| ROA | -38.4% |
| Debt/Equity | 0.04 |
| Div yield | 0.00% |

As of Nov 20, 2026

## Insider trading

[Vaxcyte, Inc. Common Stock (PCVX) insider trading](https://massive.com/quote/pcvx/insider-trading.md): open-market Form 4 buys and sells by Vaxcyte, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Vaxcyte, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 4, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 4, 2026, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026.”
- Oct 9, 2026 · Underwriting agreement
  “On October 6, 2026, Vaxcyte entered into an underwriting agreement... relating to the issuance and sale... of 7,412,500 shares of Common Stock... and pre-funded warrants to purchase 400,000 shares of its Common Stock.”
- Oct 5, 2026 · Investor presentation
  “On October 5, 2026, the Company also made available the slide presentation attached as Exhibit 99.2 to this Current Report on Form 8-K.”
- Sep 3, 2026 · Executive officer appointment
  “On August 31, 2026, Vaxcyte, Inc. (the "Company") appointed David McAvoy as the Company's Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary.”
- Jul 15, 2026 · Director appointment
  “Concurrently, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed John Markels to the Board as a Class II director, effective as of July 16, 2026. Dr. Markels' term will expire at the Company's annual meeting of stockholders in 2028. The Board also appointed Dr. Markels to serve as a member of the Audit Committee and Compensation Committee of the Board.”

## PCVX short interest

How heavily PCVX is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 6.7 |
| Short interest | 15.36M |
| Avg volume | 2.28M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## PCVX news

The latest news and headlines about Vaxcyte, Inc. Common Stock (PCVX).

- [Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?](https://www.zacks.com/stock/news/3019679/wall-street-analysts-see-an-87-35-upside-in-vaxcyte-pcvx-can-the-stock-really-move-this-high?cid=CS-ZC-FT-fundamental_analysis|consensus_price_target-3019679) · Zacks Investment Research · Oct 30, 2026 · positive sentiment
- [Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet](https://www.zacks.com/stock/news/3006993/wall-street-analysts-think-vaxcyte-pcvx-could-surge-75-6-read-this-before-placing-a-bet?cid=CS-ZC-FT-fundamental_analysis|consensus_price_target-3006993) · Zacks Investment Research · Oct 14, 2026 · positive sentiment
- [Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes](https://www.globenewswire.com/news-release/2026/10/07/3376168/0/en/vaxcyte-announces-pricing-of-concurrent-public-offerings-of-common-stock-pre-funded-warrants-and-convertible-senior-notes.html) · GlobeNewswire Inc. · Oct 6, 2026 · positive sentiment
- [Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?](https://www.zacks.com/stock/news/3000644/novavax-nvax-surges-20-1-is-this-an-indication-of-further-gains?cid=CS-ZC-FT-fundamental_analysis|daily_price_change_5%-3000644) · Zacks Investment Research · Oct 6, 2026 · positive sentiment
- [Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge](https://www.fool.com/coverage/stock-market-today/2026/10/05/stock-market-today-oct-5-tech-momentum-lifts-nasdaq-as-treasury-yields-surge/?source=iedfolrf0000001) · The Motley Fool · Oct 5, 2026 · positive sentiment

## About Vaxcyte, Inc. Common Stock

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 507 |
| Listed | Jun 12, 2020 |

[Company website](https://www.vaxcyte.com)

## FAQ

### What is the Vaxcyte, Inc. Common Stock (PCVX) stock price today?

Vaxcyte, Inc. Common Stock (PCVX) is trading at $55.39 (-5.09% on the day) as of 7:30:05 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Vaxcyte, Inc. Common Stock?

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine…

### What is the short interest in PCVX?

As of Oct 30, 2026, PCVX has 15.36M shares short and 6.7 days to cover.

### What exchange is PCVX listed on?

Vaxcyte, Inc. Common Stock (PCVX) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

## Live data

Prices here are 15-minute delayed. For real-time PCVX quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=PCVX`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Vaxcyte, Inc. Common Stock (PCVX) insider trading](https://massive.com/quote/pcvx/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
